Treatment outcomes and risk factors for severity and mortality in Clostridioides difficile infection: a single-center study in Thailand.|https://dx.doi.org/10.3855/jidc.20742
Fecal Microbiota-based therapies compared to Fecal Microbiota Transplantation for Preventing recurrent C. difficile Infection.|https://dx.doi.org/10.1016/j.cgh.2025.08.029
Bezlotoxumab for the prevention of recurrent Clostridioides difficile infection for patients with cancer.|https://dx.doi.org/10.20524/aog.2025.0994
Lipidomics, Microbiota, and Intestinal Clostridioides difficile Infection Outcome.|https://dx.doi.org/10.3390/ijms26178214
Assessment of chemical methods in the extraction of spore surface layers in Clostridioides difficile spores.|https://dx.doi.org/10.1128/msphere.00531-25
Activated PI3K Delta Syndrome: A Case Presentation and Literature Review.|https://dx.doi.org/10.7759/cureus.89884
Use of proximity ligation shotgun metagenomics to investigate the dynamics of plasmids and bacteriophages in the gut microbiome following fecal microbiota transplantation.|https://dx.doi.org/10.1080/19490976.2025.2559019
Fecal microbiota transplantation in recurrent Clostridioides difficile: Is greater methodological rigor and the analysis of other populations relevant?|https://dx.doi.org/10.1016/j.rgmxen.2025.09.022
Response to "Fecal microbiota transplantation in recurrent Clostridioides difficile: Is greater methodological rigor and the analysis of other populations relevant?".|https://dx.doi.org/10.1016/j.rgmxen.2025.09.023
De novo design of potent inhibitors of clostridial family toxins.|https://dx.doi.org/10.1073/pnas.2509329122
Patients, antibiotics and Clostridioides difficile: when your best friend becomes your worst enemy.|https://dx.doi.org/10.1093/jacamr/dlaf163
Efficacy of Fecal Microbiota Transplantation (FMT) Versus Standard Antibiotic Therapy in Recurrent Clostridioides difficile (CDI/rCDI) Infection: A Systematic Review and Meta-Analysis.|https://dx.doi.org/10.7759/cureus.90614
Unchecked Immunity to Unleashed Anarchy: A Case of Hemophagocytic Lymphohistiocytosis Following Combination Immune Checkpoint Inhibitor Therapy.|https://dx.doi.org/10.7759/cureus.90533
Gut power for better health: microbial therapeutics.|https://dx.doi.org/10.1097/MOG.0000000000001136
Microbiota-Based Therapies for Recurrent Clostridium difficile Infection: A Systematic Review of Their Efficacy and Safety.|https://dx.doi.org/10.7759/cureus.90737
Microbiomes in Health, Diseases and Therapeutics.|https://dx.doi.org/10.1016/j.amjmed.2025.09.002
The emerging view on the roles of butyrate in Clostridioides difficile pathogenesis.|https://dx.doi.org/10.1128/iai.00047-25
Soft tissue reconstruction of tumor-related proximal tibial hemiarthroplasty using synthetic mesh combined with a medial gastrocnemius flap.|https://dx.doi.org/10.1186/s10195-025-00874-7
Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial.|https://dx.doi.org/10.1016/S2468-1253(25)00190-6
Compassionate Use of Encapsulated MKB-01 Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Single-Center Experience.|https://dx.doi.org/10.3390/microorganisms13092134
Economic impact of multiple recurrent Clostridioides difficile infection in a community teaching hospital.|https://dx.doi.org/10.1017/ice.2025.10295
Insights on recurrent and sequential Clostridioides difficile infections from genomic surveillance in Minnesota, USA, 2019-2021.|https://dx.doi.org/10.1093/infdis/jiaf505
Clostridioides difficile pathogenesis and control.|https://dx.doi.org/10.1038/s41579-025-01242-2
Unravelling three-way interactions between Clostridioides difficile, microbiota and the host.|https://dx.doi.org/10.1099/jmm.0.002067
